FOSUN HEALTH Logo

Type 1 Diabetes Overview

catalogue

Type 1 Diabetes Overview

Type 1 Diabetes Overview

Type 1 diabetes is an autoimmune condition: the body's own immune system destroys the cells that make insulin, and without insulin glucose cannot leave the blood and enter the body's cells. It is not caused by eating sugar, by weight, or by anything a family did or did not do. For a century the answer has been insulin for life. This guide follows the question patients actually ask — what the diagnosis means, how the condition is staged and confirmed, and what to make of a hospital-published programme that reports patients discontinuing insulin.

Type 1 Diabetes Overview
  • patients off insulin in a hospital-published interim analysis

  • longest duration off insulin reported at publication

  • typical inpatient stay in the HIM programme

  • countries and regions our international patients come from

What Type 1 diabetes is — an autoimmune disease, not a lifestyle one

The beta cells of the pancreas are the only cells in the body that make insulin, and insulin is the hormone that allows glucose to leave the blood and enter muscle, fat and every other tissue. In Type 1 diabetes the immune system identifies those cells as foreign and destroys them — quietly over months or years, and then decisively. When enough of them are gone, insulin falls to nothing, glucose rises without limit, and the body begins to burn fat for fuel in a way that floods the blood with acid. Untreated, that state — diabetic ketoacidosis — kills. Treated with insulin, it is compatible with a full life: the condition is managed, not yet prevented or reversed.

Because the words sound alike, Type 1 is constantly mistaken for a severe form of Type 2, and the confusion does real damage. Type 2 diabetes is a disease of insulin resistance, commoner in later life and linked to weight and activity; the pancreas still makes insulin, sometimes a great deal of it. Type 1 is a different mechanism altogether: an immune attack, an absolute deficiency, and a body that cannot survive without injected insulin from the day of diagnosis. The treatment of one does not transfer to the other, and neither do the assumptions about cause.

It is also the younger face of diabetes. Most cases appear in children, teenagers and young adults, which is why the old name — juvenile diabetes — survives; but adults develop it too, and in adults it is the diagnosis most often missed, because it is assumed the age makes Type 2 certain. This guide is written for both groups, and for the parents who do most of the asking.

One more thing belongs at the start, because it is the reason this page exists in the form it does. The textbook answer to Type 1 diabetes has been insulin for life, administered for life. A hospital-published interim analysis from China — discussed honestly in the treatment page — reports patients who discontinued insulin under a structured integrative-medicine protocol. That claim is extraordinary, which is exactly why this guide reports it with its numbers attached rather than as a slogan.

The four types of diabetes, and why the label decides the treatment

"Diabetes" is a description of glucose, not of cause, and four different diseases produce it. Getting the type right is not pedantry: it decides whether tablets can work, whether the diagnosis is lifelong from day one, and whether a programme like the one described here is even applicable. The table is the shortest complete version of the distinction.

Type What is happening Typical picture What it means for treatment
Type 1 Autoimmune destruction of the beta cells; insulin production falls to nothing Children, teenagers and young adults most often, but any age; weeks of thirst, urination and weight loss, sometimes ketoacidosis at first presentation Insulin from diagnosis, for life as standard; antibody-positive by definition, which is the eligibility frame for the HIM programme
Type 2 Insulin resistance with a failing but still-working pancreas Commoner from middle age, strongly linked to weight and inactivity; often found on routine tests rather than by symptoms Diet, activity and tablets first; insulin later if needed. Autoantibodies negative
LADA Latent autoimmune diabetes of adults — the same immune attack as Type 1, moving slowly Adults, often slim, mislabelled Type 2 for months or years because tablets seem to work at first Antibody-positive: it progresses to insulin dependence, and it is Type 1 in slow motion for the purposes of this guide
MODY A single inherited gene fault affecting insulin secretion — monogenic, not autoimmune Young, with a striking family history of early diabetes across generations Some forms respond to tablets rather than insulin; genetic testing settles it

The practical trap is the middle row of this page's audience: the slim adult with fast-onset diabetes who is told it must be Type 2 and is started on tablets. If tablets fail within months, or ketoacidosis appears, the type was wrong from the beginning — and the antibody tests on the diagnosis page are how the record gets corrected.

The three stages before and at diagnosis

Type 1 diabetes has an official staging, and it is worth knowing because it reframes what the disease is: the immune attack runs for years before the first symptom, and the symptomatic illness is the third act, not the first. The staging comes from international consensus and applies to people with confirmed islet autoantibodies.

Stage What the tests show What the person notices
Stage 1 Two or more islet autoantibodies positive; glucose still normal Nothing at all. The disease is present immunologically but has not yet reached the glucose
Stage 2 Autoantibodies positive and glucose starting to swing — dysglycaemia on formal testing Still usually nothing, or the subtlest early thirst
Stage 3 Overt hyperglycaemia; C-peptide falling; symptoms begin The four Ts, and sometimes ketoacidosis — the conventional diagnosis

Two consequences follow. For relatives, staging is the logic of screening: a blood test can place a child at stage 1 years before any symptom, changing the first presentation from an emergency to a planned start. And for the insulin question, staging is the eligibility frame — the published programme reports its results by remaining islet function, which is to say by how early in this sequence the patient still is. After diagnosis there is also a period many families know as the honeymoon, in which residual beta cells briefly make the disease easier to control; it passes, and it is not remission.

The tests that settle what kind of diabetes this is

Every test on this list answers one question, and together they close it. None is difficult or exotic; the failure mode is simply not doing them, and treating the label instead of the mechanism.

Test What it measures What it answers
Glucose and HbA1c Current blood sugar and its three-month average That diabetes is present, and how severe the metabolic state is
Islet autoantibody panel Immune markers against GAD65, IA-2, ZnT8, the islet cells and insulin itself Whether the cause is autoimmune — the Type 1 signature, and the entry criterion for the programme described here
C-peptide The protein released alongside insulin; a measure of remaining beta-cell function How much insulin production survives. The 0.5 ng/ml threshold recurs throughout the published programme as the line above which outcomes were reported
Blood or urine ketones The fat-burning acids that rise when insulin is absent Whether the presentation is safe or already ketoacidosis — checked at first contact, every time

Thyroid and coeliac screening belong on the same blood draw, because the immune tendency that took the pancreas travels with company; up to a quarter of patients acquire a second autoimmune condition, most often the thyroid, and finding it early is easy while missing it is expensive.

Why patients travel to China for Type 1 diabetes

For most of the world's clinics, a Type 1 consultation ends where it began: insulin, adjusted and monitored well or badly, for life. The reason patients travel to us is the programme at Shenzhen Hengsheng Hospital — Fosun Health's chronic-disease integrative-medicine centre — which treats the disease as the immune process it is rather than only as a glucose number, and which has published interim results that argue the textbook answer is at least partly negotiable.

The programme is built on Holistic Integrative Medicine (HIM), a protocol that combines four lines of attack: precision diagnosis on mass-spectrometry platforms to identify the immune pattern in the individual patient; immune regulation through molecular nutrition and Chinese herbal medicine, aimed at quieting the attack on the islets; metabolic repair through acupuncture, herbal medicine and nutritional intervention; and continuous precision monitoring, with AI-assisted analysis of glucose and immune markers guiding adjustments between visits. An inpatient stay of three to five days establishes the protocol; follow-up runs through tele-digital healthcare rather than requiring the patient to remain in China.

How to read the results. The figures on this page come from the hospital's own published interim analysis and are presented as such. In a two-year clinical observation, 70 patients diagnosed with Type 1 diabetes were treated under the protocol; 24 of them — about a third — discontinued insulin entirely, maintaining HbA1c below 7% with C-peptide testing showing recovery of islet function, and the longest patient had been off insulin for 14 months at the time of publication. The reported pattern favours patients diagnosed early with C-peptide above 0.5 ng/ml. This is single-centre, interim data with a defined eligibility frame: it is a reason to be evaluated, not a promised outcome, and insulin remains the standard of care until an individual assessment says otherwise.

Around the programme, the practical machinery is the same as for every condition we treat. Records sent ahead receive a written specialist opinion, with an evaluation of eligibility for the protocol, before any journey is booked. We work with more than 30 commercial insurers for direct billing and have received international patients from 124 countries and regions. Follow-up after discharge runs through the programme's tele-digital platform — glucose and immune-marker data reviewed continuously, doses and protocols adjusted remotely — so the treatment does not stop at the airport.

Frequently Asked Questions

Is Type 1 diabetes caused by eating too much sugar?

No. Type 1 diabetes is an autoimmune disease: the immune system mistakes the insulin-producing beta cells of the pancreas for foreign tissue and destroys them, and the sugar in the diet has nothing to do with triggering that attack. Diet and weight matter enormously in Type 2 diabetes, which is the commoner condition, and the two are constantly confused. In Type 1 diabetes a sensible diet helps manage the condition, but no diet caused it and no diet, on its own, reverses it.

Must insulin really be taken for life?

For a century the honest answer has been yes, and insulin remains the standard of care everywhere. What has changed is that a hospital-published interim analysis from Shenzhen Hengsheng Hospital describes a structured integrative-medicine programme — HIM, combining Chinese and Western medicine — in which, of 70 patients treated over a two-year observation period, 24 discontinued insulin while maintaining stable glucose levels and measurable recovery of islet function. The longest reported duration off insulin at the time of publication was 14 months. These are single-centre, published interim results with defined eligibility: the best outcomes were seen in patients diagnosed early whose C-peptide was above 0.5 ng/ml. They are a reason to seek evaluation, not a promise of the same outcome, and insulin remains the treatment until an individual assessment says otherwise.

What is the difference between insulin independence and a cure?

A cure would mean the autoimmune attack has stopped for good and the pancreas works normally without any treatment or monitoring. Insulin independence, as reported in the programme, is narrower: islet function has recovered to a level described as sufficient for normal metabolic needs, monitored by C-peptide testing and glucose data over time. The distinction matters for expectations. Independence, where achieved, has so far been maintained with dietary management and regular follow-up rather than insulin; how durable it proves over years is a question the long-term follow-up is still answering.

Can Type 1 diabetes be detected before symptoms?

Yes, in principle. Blood tests for islet autoantibodies can identify people — most usefully the siblings and children of patients — who are in the pre-symptomatic stages of the disease, before glucose has changed and long before any symptom appears. Early detection changes the first illness: a child found at stage 1 or 2 is monitored and begins treatment before ketoacidosis, which is the complication that makes first presentations dangerous. It is also the situation in which the published programme reports its best results, because islet function is still substantially intact.

Ask the eligibility question first

Send the diagnosis records — the antibody panel if it has been done, the most recent C-peptide, HbA1c history and current insulin regimen — together with the age at diagnosis and any family history. The programme team will return a written opinion on the type, the remaining islet function the results suggest, and whether the HIM protocol is applicable, before any travel is arranged.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*